摘要
目的:探讨乳腺癌(BC)组织中肿瘤浸润淋巴细胞(TIL)、微小RNA-31-5p(miR-31-5p)、泛素蛋白连接酶E3A(UBE3A)的表达及其与生物学行为及新辅助化疗反应性间的关系。方法:选取2018年1月至2021年6月来我院就诊的BC患者93例为观察组,均进行新辅助化疗治疗,同期选取乳腺良性肿瘤患者61例为对照组。对比两组不同生物学行为病灶组织TIL、miR-31-5p、UBE3A的表达,分析TIL、miR-31-5p、UBE3A表达与新辅助化疗反应性间的关系。结果:观察组TIL、UBE3A表达高于对照组,miR-31-5p表达低于对照组,差异具有统计学意义(P<0.05);TIL、miR-31-5p、UBE3A表达与淋巴结转移、组织学分级、临床分期、分化程度、组织学类型有关(P<0.05);TIL、UBE3A高表达及miR-31-5p低表达均会增加化疗耐药风险(P<0.05);TIL、miR-31-5p、UBE3A联合预测效能高于单一指标预测(P<0.05)。结论:BC患者TIL、miR-31-5p、UBE3A表达与生物学行为有关,联合检测在治疗反应性预测中具有较高效能。
Objective: To explore the relationship between the expressions of breast cancer(BC) tumor infiltrating lymphocytes(TIL), miR-31-5p, ubiquitin protein ligase E3A(UBE3A) and biological behavior and neoadjuvant chemotherapy responsiveness. Methods: 93 BC patients attending our hospital from January 2018 to June 2021 were selected as the observation group, and they were all treated with neoadjuvant chemotherapy. 61 patients with benign breast tumors were selected as the control group during the same period. The expressions of TIL, miR-31-5p, UBE3A in focal tissues were compared between the two groups with different biological behaviors. The relationship between TIL, miR-31-5p, UBE3A expressions and neoadjuvant chemotherapy responsiveness were analyzed. Results: The expressions of TIL and UBE3A in the observation group were higher than that of the control group, and the expressions of miR-31-5p was lower than that of the control group(P<0.05).The expressions of TIL, miR-31-5p and UBE3A were related to lymph node metastasis, histological grade, clinical stage, degree of differentiation, and histological type(P<0.05). High expressions of TIL, UBE3A and low expressions of miR-31-5p would increase the risk of chemotherapy resistance(P<0.05).The combined predictive power of TIL, miR-31-5p and UBE3A was higher than that of a single index(P<0.05). Conclusion: The expressions of TIL, miR-31-5p and UBE3A in BC patients were related to biological behaviors, and combined detection had a high efficiency in predicting treatment response.
作者
贺洪洲
陈萍
梁华
周永红
李小荣
HE Hongzhou;CHEN Ping;LIANG Hua;ZHOU Yonghong;LI Xiaorong(Department of Thyroid and Breast Surgery,First People’s Hospital of Neijiang City,Neijiang 641000,China)
出处
《现代医学》
2022年第12期1500-1507,共8页
Modern Medical Journal
基金
四川省科技厅重点科研项目(2019YFS0444)
作者简介
贺洪洲(1990-),男,四川宜宾人,主治医师,医学硕士。E-mail:qq29209234@163.com;通信作者:梁华,E-mail:hhzlyt@sina.com
